Phase 2 N=15 PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Overall Response as Determined by iRECIST — 1; 1; 3; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Small Cell Prostate Cancer · Neuroendocrine Prostate Cancer · Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
Primary: Response Rate, as Assessed by CT/MRI and Bone Scan, of Treatment With MLN8237 for Patients With Neuroendocrine Prostate Cancer — 18 participants
Phase 2 N=17 Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma · Stage IV Prostate Cancer AJCC v7
Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=30 Phase 2 Study of ONC201 in Neuroendocrine Tumors
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
N/A N=11 PET Imaging in MCI Following ADT for PCa
Prostate Cancer · Mild Cognitive Impairment
Primary: PET Biomarker Uptake — 0.95; 0.98 Standard Uptake Measure SUV
N/A N=77 Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
Prostate Cancer
Primary: Acute Grade 3 or Higher Treatment-related Toxicity Rate. — 1; 3 participants — p=<0.0001
Phase 2 N=30 Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
Prostate Cancer · Recurrent Prostate Carcinoma · Stage IV Prostate Adenocarcinoma
Primary: Number of Participants With Change in PSA Response — 2; 0 Participants
Phase 2 N=41 Capecitabine and Temozolomide for Neuroendocrine Cancers
Neuroendocrine Tumors
Primary: Number of Participants With Partial Response (PR) — 9 participants
N/A N=2,313 A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Prostatic Neoplasms
Primary: Duration of Therapy (DOT) — 18.5 Months
Phase 1 N=6 Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Prostatic Neoplasms · Prostatic Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants
Phase 2 N=40 Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Prostate Cancer
Primary: Time to Disease Progression — 15.2 weeks
Phase 2 N=7 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Stage IVB Prostate Cancer AJCC v8
Primary: Overall Response Rate (ORR) — 50 percentage of participants
Phase 2 N=62 Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Neuroendocrine Cancer
Primary: Overall Response Rate (ORR) — 3.226 percentage of participants
Phase 2 N=32 Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
Phase 2 N=90 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale
Phase 2 N=27 Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…
Phase 2 N=23 Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: PSA Response — 0 participants
Phase 2 N=74 Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
Prostate Cancer
Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months
Phase 2 N=3 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: PFS
Phase 2 N=51 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Gastrin-Producing Neuroendocrine Tumor · Lung Carcinoid Tumor · Metastatic Digestive System Neuroendocrine Tumor G1
Primary: Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 6; 14; 21 participants
Phase 2 N=39 Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Prostate Cancer
Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc
Phase 2 N=6 Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With a Toxicity — 6; 7; 24 Percentage of participants
Phase 2 N=93 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
Phase 2 N=15 Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Prostate Carcinoma Metastatic in the Bone
Primary: Progression-free Survival — 38.5 percentage of participants